Chr. Hansen reaches 7% organic growth in 2018/19

Press releases   •   Oct 10, 2019 06:28 UTC

Despite more challenging growth conditions Chr. Hansen delivers a strong EBIT margin and a healthy cash flow, while also making significant progress on key strategic priorities

Chr. Hansen’s good bacteria to be produced on solar power

Press releases   •   Sep 23, 2019 08:07 UTC

A new 10-year agreement enables Chr. Hansen Denmark to switch 100% to green power from two brand new solar parks. The agreement underlines Chr. Hansen’s commitment to a sustainable future and will create more green energy capacity to the benefit of all of Denmark.

Chr. Hansens gode bakterier skal fremstilles på solenergi

Press releases   •   Sep 23, 2019 08:02 UTC

En ny tiårig aftale med Better Energy betyder, at Chr. Hansen kan overgå 100% til grøn strøm fra to helt nye solcelleparker. Aftalen understreger Chr. Hansens dedikation til en bæredygtig fremtid og skaber mere grøn energi til hele Danmark.

Chr. Hansen and Lonza’s newly branded joint venture, BacThera, receives anti-trust approvals to start contract manufacturing of live biotherapeutic products

Press releases   •   Aug 29, 2019 13:52 UTC

​Chr. Hansen Holding A/S, a leading global bioscience company, and Lonza AG, a leading pharma contract manufacturing company, announce today that they have received the relevant approvals from anti-trust regulators needed to establish the 50/50 joint venture in the emerging market for live biotherapeutic products, which was originally announced in Company Announcement No. 04 on April 2, 2019.

Chr. Hansen and Lonza’s newly branded joint venture, BacThera, receives anti-trust approvals to start contract manufacturing of live biotherapeutic products

News   •   Aug 29, 2019 09:16 UTC

​Chr. Hansen Holding A/S, a leading global bioscience company, and Lonza AG, a leading pharma contract manufacturing company, announce today that they have received the relevant approvals from anti-trust regulators needed to establish the 50/50 joint venture in the emerging market for live biotherapeutic products, which was originally announced in Company Announcement No. 04 on April 2, 2019.

Chr. Hansen gearer op til en bæredygtig fremtid

Press releases   •   Aug 29, 2019 07:39 UTC

Den globale bioscience virksomhed udvider og styrker forskning- & udviklingsfaciliteterne i Hørsholm for at imødekomme den stigende efterspørgsel efter naturlige og bæredygtige produkter.

Chr. Hansen gears up for a sustainable future

Press releases   •   Aug 29, 2019 07:38 UTC

Global bioscience company Chr. Hansen to expand and strengthen its research & development facilities north of Copenhagen to meet the increasing demand for natural and sustainable products.

Endnu en influenzasæson er på trapperne, men ny forskning har afsløret et hemmeligt våben, der kan nedbringe omkostningerne ved influenza-lignende sygdom

Press releases   •   Aug 28, 2019 07:48 UTC

En ny sundhedsøkonomisk undersøgelse har påvist, at indtagelsen af probiotika kan bidrage til at reducere omkostningerne forbundet med influenza-lignende sygdom. Alene i USA kan indtagelsen af probiotika nedbringe antallet af sygedage med over 54 millioner dage om året, ifølge undersøgelsen.

As the dreaded flu-season knocks on our door, a new study reveals a secret weapon to reduce the cost of flu-like sickness

Press releases   •   Aug 28, 2019 07:22 UTC

A new health economics study shows that the intake of probiotics can help reduce the cost of flu-like sickness. In the US alone, taking probiotics can reduce the number of sick days by over 54 million days per year, according to the study.

Solid sales growth and profitability in Q3, but reduced organic growth outlook for the year

Press releases   •   Jun 26, 2019 17:57 UTC

Chr. Hansen delivers a solid financial result of 9% organic growth for the first nine months, but adjusts full-year organic growth​ outlook from 9-11% to 7-8%

Contacts 6 contacts

  • Press Contact
  • Head of Media Relation
  • DKgqCAzfLExu@cschrvb-hbjanitsephn.macofpmix
  • +45 53 39 23 84
  • +45 45 74 76 42

  • Press Contact
  • Press officer
  • DKmcHRalE@lzchzvr-pxhaplnsptenyh.cmoomnw
  • +45 45 74 76 36
  • +45 20 74 28 40

About Chr. Hansen A/S

About us

Chr. Hansen is a leading, global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. We develop and produce cultures, enzymes, probiotics and natural colors for a rich variety of foods, confectionery, beverages, dietary supplements and even animal feed and plant protection. Our product innovation is based on more than 30,000 microbial strains – we like to refer to them as ‘good bacteria’. Our solutions enable food manufacturers to produce more with less – while also reducing the use of chemicals and other synthetic additives – which make our products highly relevant in today’s world. We have been delivering value to our partners – and, ultimately, end consumers worldwide – for over 140 years. We are proud that more than one billion people consume products containing our natural ingredients every day. Revenue in the 2017/18 financial year was EUR 1,097 million. Chr. Hansen was founded in 1874 and is listed on Nasdaq Copenhagen.

Address

  • Chr. Hansen A/S
  • Boege Allé 10-12
  • DK-2970 Hoersholm
  • Denmark